Preventing prescription opioid overdose

Journal of Clinical Outcomes Management

Volumn 17, Issue 11, 2010, Pages 33-42

  Morgan, Laura A ^a   Weaver, Michael F ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; CIPROFLOXACIN; CODEINE; CODEINE PLUS ACETAMINOPHEN; CODEINE PLUS ASPIRIN; DEXTROPROPOXYPHENE; DEXTROPROPOXYPHENE NAPSILATE; DEXTROPROPOXYPHENE PLUS PARACETAMOL; FENTANYL; FLUCONAZOLE; FLUOXETINE; HYDROMORPHONE; IBUPROFEN PLUS OXYCODONE; METHADONE; MORPHINE SULFATE; NALOXONE; NORPETHIDINE; OPIATE; OPIATE ANTAGONIST; OXYCODONE; OXYCODONE PLUS ASPIRIN; OXYCODONE PLUS PARACETAMOL; OXYMORPHONE; PARACETAMOL PLUS TRAMADOL; PENTAZOCINE; PETHIDINE; TRAMADOL; UNCLASSIFIED DRUG;

ACUTE RESPIRATORY FAILURE; ANAPHYLAXIS; ASPIRATION PNEUMONIA; CHRONIC PAIN; CLINICAL FEATURE; DECISION MAKING; DROWSINESS; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG HALF LIFE; DRUG INTOXICATION; DRUG METABOLISM; DRUG MONITORING; HEART ARRHYTHMIA; HOSPITALIZATION; HUMAN; LUNG EDEMA; PRACTICE GUIDELINE; PRESCRIPTION; QT PROLONGATION; RESPIRATORY DISTRESS; REVIEW; RISK FACTOR; SCREENING TEST; SEDATION; SEIZURE; SIDE EFFECT; TORSADE DES POINTES;

EID: 78649658062     PISSN: 10796533     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Boudreau D, Von Korff M, Rutter CM, et al. Trends in long-term opioid therapy for chronic noncancer pain. Pharmacoepidemiol Drug Saf 2009;18:1166-75.
2. Centers for Disease Control and Prevention. Emergency department visits involving nonmedical use of selected prescription drugs - U.S., 2004-2008. MMWR Morb Mortal Wkly Rep 2010;59:705-9.
3. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010;152:85-92.
4. Methadone hydrochloride tablets USP 40mg (dispersible). DEA advisory. Accessed 29 Sept 2010 at www.deadiversion.usdoj.gov/pubs/advisories/methadone- advisory.htm.
5. Andrews CM, Krantz MJ, Wedam EF, et al. Methadone-induced mortality in the treatment of chronic pain: role of QT prolongation. Cardiol J 2009;16:210-7.
6. Krantz MJ, Martin J, Stimmel B, et al. QTc interval screening in methadone treatment. Ann Intern Med 2009;150:387-95.
7. Sporer KA. Acute heroin overdose. Ann Intern Med 1999;130:584.
8. Zador D, Sunjic S, Darke S. Heroin-related deaths in New South Wales, 1992: toxicological findings and circumstances. Med J Aust 1996;164:204.
9. Weaver MF, Schnoll SH. Addiction issues in prescribing opioids for chronic nonmalignant pain. J Addiction Med 2007;1:2-10.
10. Urban BJ, France RD, Steinberger EK, et al. Long-term use of narcotic/antidepressant medication in the management of phantom limb pain. Pain 1986;24:191-6.
11. American Society of Addiction Medicine. Definitions related to the use of opioids for the treatment of pain: a consensus document from the American Academy of Pain Medicine, the American Pain Society, and the American Society of Addiction Medicine. Glenview (IL): American Academy of Pain Medicine; 2001.
12. Turk DC, Swanson KS, Gatchel RJ. Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clin J Pain 2008;24:497-508.
13. Chabal C, Erjavek MK, Jacobson L, et al. Prescription opioid abuse in chronic pain patients: clinical criteria, incidence, and prediction. Clin J Pain 1997;13:150-5.
14. Ives TJ, Chleminski PR, Hammett-Stabler CA, et al. Prediction of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 2006;6:46.
15. Butler SF, Fernandez KC, Benoit C, et al. Validation of the Revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain 2008;9:360-72.
16. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005;6:432-42.
17. Belgrade MJ, Schamber CD, Lindgren BR. The DIRE score: predicting outcomes of opioid prescribing for chronic pain. J Pain 2006;7:671-81.
18. Weaver MF, Schnoll SH. Risk assessment for opioid misuse in chronic pain treatment. Adv Pain Manage 2008;2:68-75.
19. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009;10:113-30.
20. Savage SR, Kirsh KL, Passik SD. Challenges in using opioids to treat pain in persons with substance use disorders. Addict Sci Clin Pract 2008;4:4-25.
21. Chan GM, Stajic M, Marker EK, et al. Testing positive for methadone and either a tricyclic antidepressant or a benzodiazepine is associated with an accidental overdose death: analysis of medical examiner data. Acad Emerg Med 2006;13:543-7.
22. Trescot AM, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician 2008;11:S133-53.
23. A morphine/naltrexone combination (Embeda) for pain. Med Lett Drugs Ther 2010;52(1334):22-3.
24. Sanofi-Aventis. Talwin NX (pentazocine and naloxone hydrochlorides) package insert. Bridgewater (NJ); 2008.
25. Becker WC, Fiellin DA, Desai RA. Non-medical use, abuse, and dependence on sedatives and tranquilizers among U.S. adults: psychiatric and socio-demographic correlates. Drug Alcohol Depend 2007;90:280-7.
26. Simoni-Wastila L, Yang HK. Psychoactive drug abuse in older adults. Am J Geriatr Pharmacother 2006;4:380-94.
27. Weaver MF, Schnoll SH. Hallucinogens and club drugs. In: Galanter M, Klebert HD, editors. Textbook of substance abuse treatment. 4th ed. Washington (DC): American Psychiatric Press; 2008:191-200.
28. Risk evaluation and mitigation strategies (REMS) for extended-release and long acting opioid analgesics. Joint meeting of the Anesthetic and Life Support Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. FDA communication; July 2010.
29. Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Medicine 2005;6:107-12.
30. Weaver MF, Schnoll SH. Opioid treatment of chronic pain in patients with addiction. J Pain Palliat Care Pharmacother 2002;16:5-26.
31. Weaver MF. Prescribing medications with potential for abuse. J Clin Outcomes Manage 2009;16:171-9.
32. Baca CT, Grant KJ. Take-home naloxone to reduce heroin death. Addiction 2005;100:1823-31.
33. Wermeling DP. Opioid harm reduction strategies: focus on expanded access to intranasal naloxone. Pharmacotherapy 2010;30:627-31.